BioSpace News Archive

Drug Development

Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke

Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today presented positive results of its Phase III clinical trial evaluating sovateltide as a treatment for acute ischemic stroke.

October 31, 2022
·
4 min read
Pharm Country

IO Biotech to Participate in the 2022 Jefferies London Healthcare Conference

IO Biotech announced that Mai-Britt Zocca, Ph.D., the company’s President and CEO, and Amy Sullivan, the company’s CFO, will be participating in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference, taking place November 15 – 17, 2022.

October 31, 2022
·
2 min read
Business

Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter financial results on Monday, November 7, 2022, before the market opens.

October 31, 2022
·
1 min read
Biotech Bay

Eargo Announces Commencement of Rights Offering - October 31, 2022

Eargo, Inc., a medical device company on a mission to improve the quality of life for people with hearing loss, announced that it has commenced a rights offering for up to 375 million newly issued shares of its common stock and that it has launched its rights offering website.

October 31, 2022
·
6 min read
Biotech Bay

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

ALX Oncology Holdings Inc. announced it has entered into a loan facility agreement with Oxford Finance LLC and Silicon Valley Bank for up to $100 million of non-dilutive financing.

October 31, 2022
·
5 min read
Pharm Country

Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Sidoti November Virtual Micro-Cap Conference on November 9, 2022.

October 31, 2022
·
4 min read
Biotech Bay

Epic Bio Presents First Data Supporting Persistent and Tunable Gene Activation Using Transient Delivery

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented multiple datasets demonstrating persistent gene activation at the 6th International Conference on Epigenetics and Bioengineering, on October 29, 2022, in Houston, Texas.

October 31, 2022
·
2 min read
Drug Development

Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B.

October 31, 2022
·
8 min read
Defence Therapeutics Announces Debenture Financing

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies

October 31, 2022
·
4 min read
Policy

InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the first adolescent patient has been dosed in clinical trial with its second generation pan-TRK inhibitor ICP-723 at the Sun Yat-sen University Cancer Center.

October 31, 2022
·
2 min read